This report provides comprehensive information on the therapeutic development for Ureter Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ureter Cancer and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Key Topics Covered:
- Ureter Cancer Overview
- Therapeutics Development
- Pipeline Products for Ureter Cancer - Overview
- Pipeline Products for Ureter Cancer - Comparative Analysis
- Ureter Cancer - Therapeutics under Development by Companies
- Ureter Cancer - Therapeutics under Investigation by Universities/Institutes
- Ureter Cancer Products Glance
- Late Stage Products
- Clinical Stage Products
- Early Stage Products
- Ureter Cancer - Products under Development by Companies
- Ureter Cancer - Products under Investigation by Universities/Institutes
- Ureter Cancer - Companies Involved in Therapeutics Development
- Altor BioScience Corporation
- Eisai Co., Ltd.
- Exelixis, Inc.
- Merck & Co., Inc.
For more information visit http://www.researchandmarkets.com/research/xpm2ql/ureter_cancer